Objective: To explore the safety and feasibility of neoadjuvant chemotherapy combined with Da Vinci robotic surgery system for advanced gastric cancer. Methods: The respective cross-sectional study was conducted. 151 patients were retrospectively analyzed who underwent radical gastrectomy after two cycles of neoadjuvant chemotherapy (SOX: oxaliplatin + tegafur) in the affiliated Hospital of Nanjing University of traditional Chinese Medicine from July 2018 to July 2022. According to mode of operation, all patients were divided into Da Vinci robotic radical gastrectomy group (robot group) and Laparoscopic radical gastrectomy group (laparoscopy group). The general data, perioperative surgery related indexes and postoperative rehabilitation were compared between two groups. Results: Laparoscopic radical gastrectomy vs Da Vinci robotic radical gastrectomy group: Age [65（57-69）vs 66（58-71）, P=0.228 ]years old; BMI（21.93±3.1 vs 22.76±3.09, P=0.14）Kg/m2; Tumor size [3.15（2.5-4.38）vs 3（2.3-4.5）, P=0.66]cm; Location of tumor（Cardia：Body of stomach：Gastric antrum）[（19：16：25）vs（24：18：18）, P=0.4]cases; Scope of operation（Proximal gastric：Distal gastric：total gastric）[(8：26：26) vs (15：21：24) , P=0.25]cases; Digestive tract reconstruction（Esophagogastroanastomosis：BillrothⅡ：Rou-en-Y）[(10：24：26) vs (14：19：27) , P=0.53]cases; Preoperative cTNM stage(Ⅰ：Ⅱ：Ⅲ：Ⅳ) [(0：31：29：0) vs (0：23：37：0),P=0.14]cases; pT stage[（13：5：32：10）vs（14：5：35：6）, P=0.76]cases; pN stage [（29：13：9：9）vs（26：10：10：14）, P=0.64]cases; ypTNM stage（Ⅰ：Ⅱ：Ⅲ：Ⅳ）[(18：21：21：0) vs (13：24：23：0), P=0.58]cases; Tumor differentiation（High differentiation：Intermediate differentiation：Middle-low differentiation：Poor differentiation）[(5：11：25；19) vs (8：13：23：16), P=0.75]cases; Tumor regression grade (Ryan score：0:1:2:3)[(7：7：30：16) vs (4：7：33：16), P=0.81]cases; Complete?response（7 vs 4，P=0.34）cases; Partial response（37 vs 40，P=0.57）cases; Operation time（217.42±61.5 vs 266.58±50.11,p＜0.001）min; Volume of intraoperative blood loss（92.5±55.65 vs 64.33±43,p=0.002）ml; Length of abdominal incision [10（10-12）vs 10（4-12）, P= 0.011]cm; Number of lymph nodes dissected in gastrectomy (31.4±11.12 vs 32.2±12.97, P=0.7); Number of metastatic lymph nodes [1（0-5）vs 1（0-5）, P=0.441]; Visual Analogue Scale (VAS) [3.13±0.68 vs 2.85±0.68, P=0.02]; Liquid diet time [88（72-120）vs 48（48-72）, P＜0.001]h; Exsufflation Time [72（48-72）vs 48（40-68）, P=＜0.001]h; Time of postoperative abdominal drainage tube removal [144（120-168）vs 114（96-144）, P=＜0.001]h; Postoperative hospital stay [7（6-9）vs 6（5-8）, P=0.014]d; Hospitalization cost [70932.5（59751.8-76644.8）vs 82833（71211-95597）, P＜0.001]yuan; Incidence of postoperative complications [5%（3/60）vs 8.3%（5/60）, P=0.46]; 30-day readmission [3 vs 2 , P=0.65]cases; 30-day reoperation [2 vs 1, P=0.56]cases; C-reactive protein [69.12（57.76-69.12）mg/l vs 55.27（32.7-66.3）mg/l, P=0.004]; White blood cells [10.61（8.51-12.4）vs 9.02（7.94-9.88）, P=0.001]×10^9/L; Neutrophils [8.61（6.97-10.61）vs 7.18（6.28-8.18）, P=0.001]×10^9/L; Serum Prealbumin [117.67（110.33-126.08）vs 129.33（116.75-150.92）, P＜0.001]mg/L; Interleukin-6 [9.28（9.12-9.31）vs 7.51（7.43-7.52）, P＜0.001]pg/mL，procalcitonin [0.6（0.53-0.6） vs 0.36（0.25-0.46）, P＜0.001]ng/mL. The volume of intraoperative blood loss, length of abdominal incision, VAS, liquid diet time, exsufflation time, time of postoperative abdominal drainage tube removal and postoperative hospital stay in robot group were better than those in laparoscopy group, but the time of operation and hospitalization cost were significantly worse than those of laparoscopy group. There was no significant difference in the number of lymph nodes dissected in gastrectomy, incidence of postoperative complications, 30-day readmission and 30-day reoperation in two groups. Conclusion: For advanced gastric cancer, the strategy of preoperative neoadjuvant chemotherapy combined with Da Vinci robotic surgery system is safe and feasible, and the incidence of postoperative complications is similar to laparoscopic surgery. So, Da Vinci robotic surgery system is a new candidate for neoadjuvant chemotherapy for advanced gastric cancer.